Clinical trial
p53 Vaccine for Ovarian Cancer
NCT00001827 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00001827 |
|---|---|
| Title | p53 Vaccine for Ovarian Cancer |
| Official title | Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Low Burden Adenocarcinoma of the Ovary |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasm |
| Intervention type | Biological, Procedure |
| Interventions | aldesleukin, incomplete Freund's adjuvant, p53 peptide vaccine, sargramostim, therapeutic autologous dendritic cells, in vitro-treated peripheral blood stem cell transplantation |
| Enrollment | 21 |
| Start date | Jul 26, 1999 |
| Primary completion | Dec 17, 2007 |
| Completion | Jan 25, 2013 |
| First posted | Nov 4, 1999 |
| Last update posted | Oct 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: